# Protagonist Therapeutics Turns Biotech into Royalty Compounder

> PTGX shifts from biotech to royalty-driven business with FDA-approved drugs and $300M buyback.
- Title: Protagonist Therapeutics Turns Biotech into Royalty Compounder
- Summary: PTGX shifts from biotech to royalty-driven business with FDA-approved drugs and $300M buyback. Protagonist Therapeutics (PTGX) became a royalty compounder…
- Keywords: protagonist therapeutics, ptgx, rusfertide, mimrylo, fda, royalty compounder, buyback, takeda, j&j, money, business, Protagonist
- Source: Seekingalpha — https://seekingalpha.com/article/4957287-protagonist-therapeutics-the-opt-out-that-turned-a-biotech-into-a-royalty-compounder
- Author: Equity Eagle
- Published: 2026-10-25T03:45:55+00:00
- Read time: 1 min
- Topics: protagonist therapeutics, ptgx, rusfertide, mimrylo, fda, royalty compounder, buyback, takeda, j&j, money, business
## FDA Approval Shift
Protagonist Therapeutics gained FDA approval for rusfertide as MIMRYLO, triggering $275 million in revenue.

> I last covered Protagonist Therapeutics (PTGX) about four months ago, in June, when rusfertide was still under priority review and the company held roughly $620 million in cash.
## Royalty Model Growth
PTGX secured back-end royalties and milestones from Takeda and J&J, shifting risk to partners while retaining economic upside.
## Financial Turnaround
Consensus forward earnings are nearly 4x trailing levels, with high-margin royalty streams generating $605 million annually against $220 million in expenses.
## Key takeaway

Protagonist Therapeutics (PTGX) became a royalty compounder after FDA approval of rusfertide as MIMRYLO, generating $605M annual revenue.